MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 112 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Using RFID technology to drive quality improvement.
Ben De Mendonca, Matthew C. Cheung, Simron Singh, Flay Charbonneau, Kirsty Wield, Philomena de Soudsa
2013· article· en· Journal of Clinical Oncology· Business, Management and Accounting
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
In Reply
Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci +14 more
2008· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
In Reply:
W. Mackillop, Junhua Huang, Lisa Barbera, Melissa Brouwers, George P. Browman
2004· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · insufficient_payloadconsensus · none
1
citations
affaboutgemma · no categorygpt · no categorymodels agree
Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.
Wei Fang Dai, Jaclyn Beca, Chenthila Nagamuthu, Ning Liu, Maureen Trudeau, Craig C. Earle +2 more
2021· article· en· Journal of Clinical Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Urinary metabolomics of gastric cancer.
Angela W. Chan, Pascal Mercier, Dan Schiller, Dean T. Eurich, David Broadhurst, Michael B. Sawyer
2015· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Age barrier in clinical trials: Are we truly moving forward?
Olubukola Ayodele, Aiste Linkeviciute-Koneko, Miriam O’Connor, Paula Calvert, Anne M. Horgan
2016· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · metaresearchconsensus · metaresearch
1
citations
affno abstractunlabeled
Reply to C.T. Matava et al
Sarah Alexander, John A. Kairalla, Sumit Gupta, Emily Hibbitts, Hannah Weisman, Doralina L. Anghelescu +11 more
2024· letter· fr· Journal of Clinical Oncology· Neuroscience
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
The effect of warfarin on the risk of prostate cancer
Vicky Tagalakis, Hani Tamim, Jean‐Paul Collet, Susan R. Kahn, Mark Blostein, J. A. Hanley
2006· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum-sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor maintenance treatment (NCT04239014).
Amit M. Oza, Andrew J. Pierce, Alan Lau, Nisha Kurian, Graeme Parr, S. Lao‐Sirieix +3 more
2020· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About